Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.83 |
| ▸ | GAA | P10253 | 7/20 | 0.83 |
| ▸ | POLB | P06746 | 6/20 | 0.83 |
| ▸ | MAPT | P10636 | 5/20 | 0.83 |
| ▸ | XDH | P47989 | 3/20 | 0.83 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.83 |
| ▸ | HES1 | Q14469 | 2/20 | 0.83 |
| ▸ | FANCF | Q9NPI8 | 2/20 | 0.83 |
| ▸ | KDM1A | O60341 | 2/20 | 0.83 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.83 |
| ▸ | MAOA | P21397 | 2/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.83 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.83 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.83 |
| ▸ | CFTR | P13569 | 1/20 | 0.83 |
| ▸ | ACHE | P22303 | 1/20 | 0.83 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.83 |
| ▸ | BACE1 | P56817 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20802110 | 1.00 | KDM4E (0.83) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL20801873 | 1.00 | KDM4E (0.83) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL30096465 | 0.97 | KDM4E (0.88) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL29366789 | 0.96 | P4HB (0.88) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL14417016 | 0.96 | P4HB (0.88) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL1566365 | 0.96 | P4HB (0.88) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL14420999 | 0.96 | P4HB (0.88) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL31720515 | 0.96 | P4HB (0.90) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL20801984 | 0.96 | P4HB (0.90) | KDM4EGAAPOLBMAPTXDH | |
| SCHEMBL30772282 | 0.96 | P4HB (0.90) | KDM4EGAAPOLBMAPTXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765128-B2 | Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2020-09-08 | — | — | US | disclosed |
| US-20190075823-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10765128-B2 | Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients | GPX1, GSTP1, GSS | KDM4E 4058/4885GAA 92/4885POLB 2591/4885 |
| US-20190075823-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS | GPX1, GSTP1, PON1 | KDM4E 4169/4885GAA 144/4885POLB 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.